The outlook of companies tied to flagship drugs like Viagra presents a nuanced investment scenario . While the initial rise of copyright, fueled by Viagra's remarkable popularity, generated substantial returns, the expiry in key regions has introduced significant volatility. Investors are now facing the impact of lower-cost alternatives, reduced in